1. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P1163A
    D[LEU4,LYS8]-VP TFA 99.29%
    D[LEU4,LYS8]-VP TFA is a selective agonist of vasopressin V1b receptor, with the Kis of 0.16 nM, 0.52 nM, and 0.1.38 nM for rat, human and mouse V1b receptor, respectively. D[LEU4,LYS8]-VP TFA has weak antidiuretic, vasopressor, and in vitro oxytocic activities.
    D[LEU4,LYS8]-VP TFA
  • HY-P2310A
    Defensin HNP-1 human TFA 99.91%
    Defensin HNP-1 human TFA is a Human neutrophil peptides (HNPs), involved in endothelial cell dysfunction at the time of early atherosclerotic development. Defensin HNP-1 human TFA exhibits broad antimicrobial and anti-leishmanial activities.
    Defensin HNP-1 human TFA
  • HY-P3162A
    (Ala13)-Apelin-13 TFA 98.78%
    (Ala13)-Apelin-13 TFA is a potent apelin receptors (APJ) antagonist. (Ala13)-Apelin-13 TFA inhibits gastric motility through vagal cholinergic pathway.
    (Ala13)-Apelin-13 TFA
  • HY-P6365B
    APP-018 452782-06-8 99.80%
    APP-018 (D-4F) is 18 D-amino acids peptide that mimics apolipoprotein A-I (apoA-I). APP-018 improves the anti-inflammatory activity of high-density lipoprotein (HDL). APP-018 can be used in researches of cardiovascular diseases.
    APP-018
  • HY-P99546
    Trebananib 894356-79-7 ≥99.0%
    Trebananib (2xCon4C) is an Fc fusion peptibody. Trebananib exerts its effects by blocking the binding of angiopoietin 1 (Ang1) and angiopoietin 2 (Ang2) to the TIE2 receptor. Trebananib has anti-angiogenic and anti-tumor activities.
    Trebananib
  • HY-103293A
    Lys-Bradykinin TFA 99.85%
    Lys-Bradykinin TFA is the TFA salt form of Lys-Bradykinin (HY-103293). Lys-Bradykinin TFA is a ligand for kallidin and bradykinin receptor, which can be generated by kininogen protein through enzymatic cleavage by the protease kallikrein. Lys-Bradykinin TFA serves as a vasodilator, which widens blood vessels and increases blood flow. Lys-Bradykinin TFA stimulates net Na+ influx, and contributes to DNA synthesis. Lys-Bradykinin TFA involves in vascular regulation, inflammation and pain sensation.
    Lys-Bradykinin TFA
  • HY-105239A
    Selepressin acetate 98.77%
    Selepressin (FE 202158) acetate is a selective vasopressin V1A receptor agonist. Selepressin acetate is a potent vasopressin. Selepressin acetate can be used in the study of septic shock.
    Selepressin acetate
  • HY-120006A
    (rel)-AR234960 1408311-94-3 98.95%
    (rel)-AR234960 is a selective and competitive agonist of the G protein-coupled receptor MAS. (rel)-AR234960 binds to the MAS receptor to activate the downstream ERK1/2 signaling pathway, inducing the expression of connective tissue growth factor (CTGF) and its downstream collagen subtype genes (such as COL1A1, COL3A1). (rel)-AR234960 promotes collagen synthesis in cardiac fibroblasts through the MAS-ERK1/2-CTGF pathway and aggravates extracellular matrix remodeling. (rel)-AR234960's in vitro effect can be blocked by the MAS inverse agonist AR244555 and MEK1 inhibitor. (rel)-AR234960 regulates the expression of cardiac fibrosis-related genes and can be used in the study of heart failure.
    (rel)-AR234960
  • HY-128747A
    α-D-Glucose-1-phosphate disodium hydrate 230954-92-4 98.0%
    α-D-Glucose-1-phosphate disodium hydrate is used as a starting material for synthesis of glucuronic acid. α-D-Glucose-1-phosphate disodium hydrate can be used as a cytostatic compound essential for cardiopathic therapy, as an antibiotic, as an immunosuppressive agent, and as a circulatory system therapy element.
    α-D-Glucose-1-phosphate disodium hydrate
  • HY-N0830S4
    Palmitic acid-d2 62689-96-7 98.0%
    Palmitic acid-d2 is the deuterium labeled Palmitic acid. Palmitic acid is a long-chain saturated fatty acid commonly found in both animals and plants. Palmitic acid can induce the expression of glucose-regulated protein 78 (GRP78) and CCAAT/enhancer binding protein homologous protein (CHOP) in in mouse granulosa cells.
    Palmitic acid-d2
  • HY-P990294
    Anti-Mouse CD106/VCAM-1 Antibody (M/K-2.7)
    Anti-Mouse CD106/VCAM-1 Antibody (M/K-2.7) is an anti-mouse CD106/VCAM-1 IgG1 monoclonal antibody. Anti-Mouse CD106/VCAM-1 Antibody (M/K-2.7) reduces inflammatory response and oxidative stress by lowering p-STAT3 and reactive oxygen species (ROS) levels. Anti-Mouse CD106/VCAM-1 Antibody (M/K-2.7) can alleviate cardiac inflammation and fibrosis by reducing the expression of collagen I and collagen III. Anti-Mouse CD106/VCAM-1 Antibody (M/K-2.7) can be used for research on cardiovascular conditions such as hypertensive heart condition and subretinal fibrosis.
    Anti-Mouse CD106/VCAM-1 Antibody (M/K-2.7)
  • HY-W013724
    Inosine-5'-diphosphate disodium 54735-61-4 99.08%
    Inosine-5'-diphosphate disodium (IDP disodium) is a decoy substrate of NM23-H2. Inosine-5'-diphosphate disodium has a superior bond capacity on GDP-binding pocket of NM23-H2 (KD: 5.0 μM). Inosine-5'-diphosphate disodium abrogates c-MYC transcription, induces apoptosis and G2/M cell cycle arrest by disrupting NM23-H2-Pu27-GQ interactions without affecting NM23-H2-mediated kinase properties. Inosine-5'-diphosphate disodium has antihypoxic, antihyperthermic and antiarrhythmic activity and protects animals against the noxious effects of γ-irradiation. Inosine-5'-diphosphate disodium can be used for cancers like Burkitt's lymphoma and cardiovascular diseases research.
    Inosine-5'-diphosphate disodium
  • HY-W042301
    Xipamide 14293-44-8 ≥98.0%
    Xipamide is a sulfonamide-based diuretic. Xipamide is an antihypertensive agent able to selectively inhibit the anion exchanger (AE).
    Xipamide
  • HY-W127530
    α-Tocopherol phosphate disodium 60934-46-5 98.01%
    α-Tocopherol phosphate disodium is an antioxidant that protects against long-wave UVA1 induced cell death and scavenge UVA1 induced ROS in a skin cell model. α-Tocopherol phosphate disodium exhibits angiogenesis-promoting activity.
    α-Tocopherol phosphate disodium
  • HY-W181102
    NFAT Inhibitor-2 422546-87-0 98.42%
    NFAT Inhibitor-2 is a potent inhibitor of calcineurin NFAT signalling. Calcineurin is a serine/threonine protein phosphatase regulated by Ca2+ and calmodulin. NFAT Inhibitor-2 has the potential for the research of inflammatory disease, an autoimmune disorder, a cardiovascular disease, a neurodegenerative disease, a disease occurring with uncontrolled cell proliferation and/or differentiation, an angiogenesis-related disease, an allergy, anaphylaxis and alopecia (extracted from patent WO2016207212A1, compound 17).
    NFAT Inhibitor-2
  • HY-W674241
    4-Ethylphenyl sulfate 85734-98-1
    4-Ethylphenyl sulfate is a gut microbial metabolite. 4-Ethylphenyl sulfate is also a protein-bound uremic toxin, a xenobiotic substrate, and causes endothelial dysfunction.
    4-Ethylphenyl sulfate
  • HY-12115
    NG-nitro-L-arginine 2149-70-4
    NG-nitro-L-arginine (Nω-nitro-L-arginine) is a NO Synthase inhibitor, with Kis of 0.61 μM (nNOS), 4.28 μM (iNOS), 0.72 μM (eNOS) respectively. NG-nitro-L-arginine inhibits endothelium-derived relaxing factor (EDRF) formation and release. NG-nitro-L-arginine inhibits portal-systemic shunting in portal-hypertensive rats, and increases blood pressure.
    NG-nitro-L-arginine
  • HY-14254A
    Olprinone 106730-54-5 99.29%
    Olprinone (Loprinone) is a potent phosphodiesterase (PDE) 3 inhibitor, with IC50s of 150, 100, 0.35 and 14 μM for PDE1, PDE2, PDE3 and PDE4, respectively. Olprinone is used for the research of heart failure due to its positive inotropic and vasodilative effects. Anti-inflammatory activity.
    Olprinone
  • HY-144390
    (S)-S007-1558 1327156-14-8 99.78%
    (S)-S007-1558 (compound 5) is a glycoprotein VI (GPVI) platelet receptor antagonist. (S)-S007-1558 inhibits collagen-induced platelet aggregation with an IC50 of 25.3 μM.
    (S)-S007-1558
  • HY-145564
    Emprumapimod 765914-60-1 99.04%
    Emprumapimod (PF-07265803) is a potent, orally active and selective inhibitor of p38α MAPK directly inhibits LPS-induced IL-6 production from RPMI-8226 cell (IC50=100 pM). Emprumapimod can be used for the research of dilated cardiomyopathy and acute inflammatory pain.
    Emprumapimod
Cat. No. Product Name / Synonyms Application Reactivity